Interferon Beta-1a
- Atc Codes:L03AB07
- CAS Codes:145258-61-3
- PHARMGKB ID:145258-61-3
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Avonex, Rebif; Belgium: Avonex, Rebif; Bulgaria: Avonex, Rebif; Cyprus: Avonex; Czech Republic: Avonex, Rebif; Denmark: Avonex, Rebif; Estonia: Avonex, Rebif; Finland: Avonex, Rebif; France: Avonex, Rebif; Germany: Avonex, Rebif; Greece: Avonex, Rebif; Hungary: Avonex, Rebif; Ireland: Avonex, Rebif; Italy: Avonex, Rebif; Latvia: Avonex, Rebif; Lithuania: Avonex, Rebif; Luxembourg: Avonex, Rebif; Malta: Avonex, Rebif; Netherlands: Avonex, Rebif; Poland: Avonex, Rebif; Portugal: Avonex, Rebif; Romania: Avonex; Slovakia: Avonex, Rebif; Slovenia: Avonex, Rebif; Spain: Avonex, Rebif; Sweden: Avonex, Rebif; UK: Avonex, Rebif.
North America
Canada: Avonex, Rebif; USA: Avonex, Rebif.
Latin America
Argentina: Rebif; Brazil: Rebif; Mexico: Avonex, Xerfelan.
Asia
Japan: Avonex.
Drug combinations
Chemistry
Interferon Beta-1a: C~908~H~1406~N~246~O~252~S~7~ (protein moiety). Mw: 20024.85 (protein moiety). Interferon beta-1a is a glycosylate polypeptide consisting of 166 aa residues produced from cultured Chinese hamster ovary cells containing the engineered gene for human interferon beta. Glycosylation occurs at the asparagine (Asn) residue at position 80. The glycoprotein is approximately 89% protein and 11% carbohydrate by weight. Interferon β~1~ (human fibroblast protein moiety). CAS-145258-61-3 (1993).
Pharmacologic Category
Biologic Response Modifiers. (ATC-Code: L03AB07).
Mechanism of action
Alters expression and response to surface antigens and can enhance immune cell activities.
Therapeutic use
Treatment of relapsing forms of multiple sclerosis.
Pregnancy and lactiation implications
There are no adequate, well-controlled studies in pregnant women. Dose-related abortifacient activity reported in Rhesus monkeys. Not recommended during lactation (potential for serious adverse reactions).
Unlabeled use
Contraindications
Hypersensitivity to natural or recombinant interferons, human albumin, or any other component of the formulation.
Warnings and precautions
Allergic reactions, including anaphylaxis, reported. Autoimmune disorders, including idiopathic thrombocytopenia, hyper-/hypothyroidism and rarely autoimmune hepatitis reported. Pancytopenia (rare) and thrombocytopenia reported (use with caution in bone marrow suppression). Possible flu-like symptoms. Rare cases of severe hepatic injury, including hepatic failure, reported. Avoid use in severe psychiatric disorders and use caution in history of depression. Use with caution in pre-existing cardiovascular disease, including angina, heart failure, and/or arrythmia. Use with caution in hepatic impairment or in cases of alcohol abuse. Use with caution in history of seizure disorder. Some formulations contain albumin (contraindicated in albumin-sensitive patients).